Australian Clinical Labs Limited (Premium)



Ticker code: ASX:ACL

ASX:ACL Red Flags & Risk Indicators
⚠️
⚠️ RED FLAGS: 1 identified

  • More Net Debt Than Equity

Income Statement
Revenue 2024 Per Share Revenue 2025e Per Share Revenue 2026e Per Share Revenue 24 to 25e [%] Revenue 25e to 26e [%] EBITDA 2024 Per Share EBITDA 2025e Per Share EBITDA 2026e Per Share EBITDA 24 to 25e [%] EBITDA 25e to 26e [%]
3.4502 3.8179 4.00309 10.7 4.9 0.94632 1.04312 1.10894 10.2 6.3
ASX:ACL Revenue Per Share (2012–2027)
Australian Clinical Labs Limited (ASX:ACL) Revenue Chart 2012–2027
ASX:ACL Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) Per Share (2012–2027)
Australian Clinical Labs Limited (ASX:ACL) EBITDA Chart 2012–2027
ASX:ACL Normalised Earnings Per Share (EPS) (2012–2027)
Australian Clinical Labs Limited (ASX:ACL) Normalised EPS Chart (2012–2027)

Valuation
Price To Sales Price To Book PER 2023 PER 2024 13Y Median PER Low PER 2025e 13Y Median PER High PER 2026e Last Updated
0.7 2.8 13.2 15.7 13.2 13.9 21.0 13.2 10/5/25
ASX:ACL Yearly Price Earnings Ratio (PER) Highs and Lows
Australian Clinical Labs Limited (ASX:ACL) PER Highs and Lows (2012–2027)
ASX:ACL Weekly Price Chart with Average True Range (ATR) Trailing Stop (10-Year View)
Australian Clinical Labs Limited (ASX:ACL) 10-Year Weekly ATR Trailing Stop Price Chart


Leave a Reply

Your email address will not be published. Required fields are marked *